-
1
-
-
70349393145
-
-
U.S. Renal Data System, USRDS 2010 Annual Data Report: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
-
U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
-
(2010)
Atlas of Chronic Kidney Disease and End-stage Renal Disease in the United States
-
-
-
2
-
-
33748949733
-
Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies
-
Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P: Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70:1318-1324, 2006
-
(2006)
Kidney Int
, vol.70
, pp. 1318-1324
-
-
Zannad, F.1
Kessler, M.2
Lehert, P.3
Grunfeld, J.P.4
Thuilliez, C.5
Leizorovicz, A.6
Lechat, P.7
-
3
-
-
22344458137
-
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
-
Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248, 2005
-
(2005)
N Engl J Med
, vol.353
, pp. 238-248
-
-
Wanner, C.1
Krane, V.2
Marz, W.3
Olschewski, M.4
Mann, J.F.5
Ruf, G.6
Ritz, E.7
-
4
-
-
63849163945
-
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
-
Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395-1407, 2009
-
(2009)
N Engl J Med
, vol.360
, pp. 1395-1407
-
-
Fellstrom, B.C.1
Jardine, A.G.2
Schmieder, R.E.3
Holdaas, H.4
Bannister, K.5
Beutler, J.6
Chae, D.W.7
Chevaile, A.8
Cobbe, S.M.9
Gronhagen-Riska, C.10
De Lima, J.J.11
Lins, R.12
Mayer, G.13
McMahon, A.W.14
Parving, H.H.15
Remuzzi, G.16
Samuelsson, O.17
Sonkodi, S.18
Sci, D.19
Suleymanlar, G.20
Tsakiris, D.21
Tesar, V.22
Todorov, V.23
Wiecek, A.24
Wuthrich, R.P.25
Gottlow, M.26
Johnsson, E.27
Zannad, F.28
more..
-
5
-
-
79959746706
-
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
-
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377:2181-2192, 2011
-
(2011)
Lancet
, vol.377
, pp. 2181-2192
-
-
Baigent, C.1
Landray, M.J.2
Reith, C.3
Emberson, J.4
Wheeler, D.C.5
Tomson, C.6
Wanner, C.7
Krane, V.8
Cass, A.9
Craig, J.10
Neal, B.11
Jiang, L.12
Hooi, L.S.13
Levin, A.14
Agodoa, L.15
Gaziano, M.16
Kasiske, B.17
Walker, R.18
Massy, Z.A.19
Feldt-Rasmussen, B.20
Krairittichai, U.21
Ophascharoensuk, V.22
Fellstrom, B.23
Holdaas, H.24
Tesar, V.25
Wiecek, A.26
Grobbee, D.27
de Zeeuw, D.28
Gronhagen-Riska, C.29
Dasgupta, T.30
Lewis, D.31
Herrington, W.32
Mafham, M.33
Majoni, W.34
Wallendszus, K.35
Grimm, R.36
Pedersen, T.37
Tobert, J.38
Armitage, J.39
Baxter, A.40
Bray, C.41
Chen, Y.42
Chen, Z.43
Hill, M.44
Knott, C.45
Parish, S.46
Simpson, D.47
Sleight, P.48
Young, A.49
Collins, R.50
more..
-
6
-
-
0037137562
-
Effect of dialysis dose and membrane flux in maintenance hemodialysis
-
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010-2019, 2002
-
(2002)
N Engl J Med
, vol.347
, pp. 2010-2019
-
-
Eknoyan, G.1
Beck, G.J.2
Cheung, A.K.3
Daugirdas, J.T.4
Greene, T.5
Kusek, J.W.6
Allon, M.7
Bailey, J.8
Delmez, J.A.9
Depner, T.A.10
Dwyer, J.T.11
Levey, A.S.12
Levin, N.W.13
Milford, E.14
Ornt, D.B.15
Rocco, M.V.16
Schulman, G.17
Schwab, S.J.18
Teehan, B.P.19
Toto, R.20
more..
-
7
-
-
35349004713
-
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients
-
Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72:1130-1137, 2007
-
(2007)
Kidney Int
, vol.72
, pp. 1130-1137
-
-
Suki, W.N.1
Zabaneh, R.2
Cangiano, J.L.3
Reed, J.4
Fischer, D.5
Garrett, L.6
Ling, B.N.7
Chasan-Taber, S.8
Dillon, M.A.9
Blair, A.T.10
Burke, S.K.11
-
8
-
-
0032572913
-
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
-
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
-
(1998)
N Engl J Med
, vol.339
, pp. 584-590
-
-
Besarab, A.1
Bolton, W.K.2
Browne, J.K.3
Egrie, J.C.4
Nissenson, A.R.5
Okamoto, D.M.6
Schwab, S.J.7
Goodkin, D.A.8
-
9
-
-
24944590527
-
The role of daily dialysis in the control of hyperphosphatemia
-
Achinger SG, Ayus JC: The role of daily dialysis in the control of hyperphosphatemia. Kidney Int Suppl 95:S28-S32, 2005
-
(2005)
Kidney Int Suppl
, vol.95
-
-
Achinger, S.G.1
Ayus, J.C.2
-
10
-
-
2342426601
-
Cardiovascular effects of frequent intensive hemodialysis
-
Chan CT: Cardiovascular effects of frequent intensive hemodialysis. Semin Dial 17:99-103, 2004
-
(2004)
Semin Dial
, vol.17
, pp. 99-103
-
-
Chan, C.T.1
-
11
-
-
64849091031
-
Cardiovascular effects of home intensive hemodialysis
-
Chan CT: Cardiovascular effects of home intensive hemodialysis. Adv Chronic Kidney Dis 16:173-178, 2009
-
(2009)
Adv Chronic Kidney Dis
, vol.16
, pp. 173-178
-
-
Chan, C.T.1
-
12
-
-
78650401348
-
Electrolyte management in frequent home hemodialysis
-
King RS, Glickman JD: Electrolyte management in frequent home hemodialysis. Semin Dial 23:571-574, 2010
-
(2010)
Semin Dial
, vol.23
, pp. 571-574
-
-
King, R.S.1
Glickman, J.D.2
-
13
-
-
73849122327
-
More intensive hemodialysis
-
Kliger AS: More intensive hemodialysis. Clin J Am Soc Nephrol 4(Suppl 1):S121-S124, 2009
-
(2009)
Clin J Am Soc Nephrol
, vol.4
, Issue.SUPPL. 1
-
-
Kliger, A.S.1
-
14
-
-
8644238766
-
Is more frequent hemodialysis beneficial and what is the evidence?
-
Lindsay RM, Nesrallah G, Suri R, Garg A, Moist L: Is more frequent hemodialysis beneficial and what is the evidence? Curr Opin Nephrol Hypertens 13:631-635, 2004
-
(2004)
Curr Opin Nephrol Hypertens
, vol.13
, pp. 631-635
-
-
Lindsay, R.M.1
Nesrallah, G.2
Suri, R.3
Garg, A.4
Moist, L.5
-
15
-
-
0142157722
-
Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis
-
Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S: Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 42:1020-1035, 2003
-
(2003)
Am J Kidney Dis
, vol.42
, pp. 1020-1035
-
-
Ting, G.O.1
Kjellstrand, C.2
Freitas, T.3
Carrie, B.J.4
Zarghamee, S.5
-
16
-
-
9144220804
-
Early clinical, quality-of-life, and biochemical changes of "daily hemodialysis" (6 dialyses per week)
-
Williams AW, Chebrolu SB, Ing TS, Ting G, Blagg CR, Twardowski ZJ, Woredekal Y, Delano B, Gandhi VC, Kjellstrand CM: Early clinical, quality-of-life, and biochemical changes of "daily hemodialysis" (6 dialyses per week). Am J Kidney Dis 43:90-102, 2004
-
(2004)
Am J Kidney Dis
, vol.43
, pp. 90-102
-
-
Williams, A.W.1
Chebrolu, S.B.2
Ing, T.S.3
Ting, G.4
Blagg, C.R.5
Twardowski, Z.J.6
Woredekal, Y.7
Delano, B.8
Gandhi, V.C.9
Kjellstrand, C.M.10
-
17
-
-
78649806628
-
In-center hemodialysis six times per week versus three times per week
-
Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS: In-center hemodialysis six times per week versus three times per week. N Engl J Med 363:2287-2300, 2010
-
(2010)
N Engl J Med
, vol.363
, pp. 2287-2300
-
-
Chertow, G.M.1
Levin, N.W.2
Beck, G.J.3
Depner, T.A.4
Eggers, P.W.5
Gassman, J.J.6
Gorodetskaya, I.7
Greene, T.8
James, S.9
Larive, B.10
Lindsay, R.M.11
Mehta, R.L.12
Miller, B.13
Ornt, D.B.14
Rajagopalan, S.15
Rastogi, A.16
Rocco, M.V.17
Schiller, B.18
Sergeyeva, O.19
Schulman, G.20
Ting, G.O.21
Unruh, M.L.22
Star, R.A.23
Kliger, A.S.24
more..
-
18
-
-
33846861959
-
Frequent Hemodialysis Network (FHN) randomized trials: study design
-
Suri RS, Garg AX, Chertow GM, Levin NW, Rocco MV, Greene T, Beck GJ, Gassman JJ, Eggers PW, Star RA, Ornt DB, Kliger AS: Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int 71:349-359, 2007
-
(2007)
Kidney Int
, vol.71
, pp. 349-359
-
-
Suri, R.S.1
Garg, A.X.2
Chertow, G.M.3
Levin, N.W.4
Rocco, M.V.5
Greene, T.6
Beck, G.J.7
Gassman, J.J.8
Eggers, P.W.9
Star, R.A.10
Ornt, D.B.11
Kliger, A.S.12
-
19
-
-
0014806388
-
Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study
-
Kannel WB, Gordon T, Castelli WP, Margolis JR: Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 72:813-822, 1970
-
(1970)
Ann Intern Med
, vol.72
, pp. 813-822
-
-
Kannel, W.B.1
Gordon, T.2
Castelli, W.P.3
Margolis, J.R.4
-
20
-
-
0014548374
-
Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study
-
Kannel WB, Gordon T, Offutt D: Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 71:89-105, 1969
-
(1969)
Ann Intern Med
, vol.71
, pp. 89-105
-
-
Kannel, W.B.1
Gordon, T.2
Offutt, D.3
-
21
-
-
77956395493
-
Echocardiographic quantification of left ventricular mass: prognostic implications
-
Swamy RS, Lang RM: Echocardiographic quantification of left ventricular mass: prognostic implications. Curr Cardiol Rep 12:277-282, 2010
-
(2010)
Curr Cardiol Rep
, vol.12
, pp. 277-282
-
-
Swamy, R.S.1
Lang, R.M.2
-
22
-
-
0028035369
-
Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
-
Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 90:1786-1793, 1994
-
(1994)
Circulation
, vol.90
, pp. 1786-1793
-
-
Levy, D.1
Salomon, M.2
D'Agostino, R.B.3
Belanger, A.J.4
Kannel, W.B.5
-
23
-
-
0035797832
-
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
-
Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104:1615-1621, 2001
-
(2001)
Circulation
, vol.104
, pp. 1615-1621
-
-
Mathew, J.1
Sleight, P.2
Lonn, E.3
Johnstone, D.4
Pogue, J.5
Yi, Q.6
Bosch, J.7
Sussex, B.8
Probstfield, J.9
Yusuf, S.10
-
24
-
-
8544223585
-
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events
-
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292:2343-2349, 2004
-
(2004)
JAMA
, vol.292
, pp. 2343-2349
-
-
Okin, P.M.1
Devereux, R.B.2
Jern, S.3
Kjeldsen, S.E.4
Julius, S.5
Nieminen, M.S.6
Snapinn, S.7
Harris, K.E.8
Aurup, P.9
Edelman, J.M.10
Wedel, H.11
Lindholm, L.H.12
Dahlof, B.13
-
25
-
-
0031963796
-
Prognostic significance of serial changes in left ventricular mass in essential hypertension
-
Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48-54, 1998
-
(1998)
Circulation
, vol.97
, pp. 48-54
-
-
Verdecchia, P.1
Schillaci, G.2
Borgioni, C.3
Ciucci, A.4
Gattobigio, R.5
Zampi, I.6
Reboldi, G.7
Porcellati, C.8
-
26
-
-
41349100305
-
Regression of echocardiographic left ventricular hypertrophy after 2years of therapy reduces cardiovascular risk in patients with essential hypertension
-
Pierdomenico SD, Lapenna D, Cuccurullo F: Regression of echocardiographic left ventricular hypertrophy after 2years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 21:464-470, 2008
-
(2008)
Am J Hypertens
, vol.21
, pp. 464-470
-
-
Pierdomenico, S.D.1
Lapenna, D.2
Cuccurullo, F.3
-
27
-
-
0037160968
-
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
-
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003, 2002
-
(2002)
Lancet
, vol.359
, pp. 995-1003
-
-
Dahlof, B.1
Devereux, R.B.2
Kjeldsen, S.E.3
Julius, S.4
Beevers, G.5
de Faire, U.6
Fyhrquist, F.7
Ibsen, H.8
Kristiansson, K.9
Lederballe-Pedersen, O.10
Lindholm, L.H.11
Nieminen, M.S.12
Omvik, P.13
Oparil, S.14
Wedel, H.15
-
28
-
-
8544226268
-
Prognostic significance of left ventricular mass change during treatment of hypertension
-
Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B: Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292:2350-2356, 2004
-
(2004)
JAMA
, vol.292
, pp. 2350-2356
-
-
Devereux, R.B.1
Wachtell, K.2
Gerdts, E.3
Boman, K.4
Nieminen, M.S.5
Papademetriou, V.6
Rokkedal, J.7
Harris, K.8
Aurup, P.9
Dahlof, B.10
-
29
-
-
1642545133
-
Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression
-
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS: Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65:1492-1498, 2004
-
(2004)
Kidney Int
, vol.65
, pp. 1492-1498
-
-
Zoccali, C.1
Benedetto, F.A.2
Mallamaci, F.3
Tripepi, G.4
Giacone, G.5
Stancanelli, B.6
Cataliotti, A.7
Malatino, L.S.8
-
30
-
-
0034056792
-
Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease
-
Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11:912-916, 2000
-
(2000)
J Am Soc Nephrol
, vol.11
, pp. 912-916
-
-
Foley, R.N.1
Parfrey, P.S.2
Kent, G.M.3
Harnett, J.D.4
Murray, D.C.5
Barre, P.E.6
-
31
-
-
36749072988
-
Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study
-
Kessler M, Zannad F, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P: Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study. Nephrol Dial Transplant 22:3573-3579, 2007
-
(2007)
Nephrol Dial Transplant
, vol.22
, pp. 3573-3579
-
-
Kessler, M.1
Zannad, F.2
Lehert, P.3
Grunfeld, J.P.4
Thuilliez, C.5
Leizorovicz, A.6
Lechat, P.7
-
32
-
-
0028150830
-
Effect of regression to the mean in serial echocardiographic measurements of left ventricular mass. Quantification and clinical implications
-
Herpin D, Demange J: Effect of regression to the mean in serial echocardiographic measurements of left ventricular mass. Quantification and clinical implications. Am J Hypertens 7:824-828, 1994
-
(1994)
Am J Hypertens
, vol.7
, pp. 824-828
-
-
Herpin, D.1
Demange, J.2
-
33
-
-
0035195246
-
Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study
-
London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12:2759-2767, 2001
-
(2001)
J Am Soc Nephrol
, vol.12
, pp. 2759-2767
-
-
London, G.M.1
Pannier, B.2
Guerin, A.P.3
Blacher, J.4
Marchais, S.J.5
Darne, B.6
Metivier, F.7
Adda, H.8
Safar, M.E.9
-
34
-
-
0030805521
-
Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance
-
DeOreo PB: Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 30:204-212, 1997
-
(1997)
Am J Kidney Dis
, vol.30
, pp. 204-212
-
-
DeOreo, P.B.1
-
35
-
-
0038439419
-
Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients
-
Lowrie EG, Curtin RB, LePain N, Schatell D: Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis 41:1286-1292, 2003
-
(2003)
Am J Kidney Dis
, vol.41
, pp. 1286-1292
-
-
Lowrie, E.G.1
Curtin, R.B.2
LePain, N.3
Schatell, D.4
-
36
-
-
12444272603
-
Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS)
-
Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ, Port FK: Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 64:339-349, 2003
-
(2003)
Kidney Int
, vol.64
, pp. 339-349
-
-
Mapes, D.L.1
Lopes, A.A.2
Satayathum, S.3
McCullough, K.P.4
Goodkin, D.A.5
Locatelli, F.6
Fukuhara, S.7
Young, E.W.8
Kurokawa, K.9
Saito, A.10
Bommer, J.11
Wolfe, R.A.12
Held, P.J.13
Port, F.K.14
-
37
-
-
77749326482
-
A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients
-
Lacson E Jr, Xu J, Lin SF, Dean SG, Lazarus JM, Hakim RM: A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients. Clin J Am Soc Nephrol 5:252-260, 2010
-
(2010)
Clin J Am Soc Nephrol
, vol.5
, pp. 252-260
-
-
Lacson Jr, E.1
Xu, J.2
Lin, S.F.3
Dean, S.G.4
Lazarus, J.M.5
Hakim, R.M.6
-
38
-
-
33644988750
-
Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy
-
Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI: Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 47:488-495, 2006
-
(2006)
Hypertension
, vol.47
, pp. 488-495
-
-
Kennedy, D.J.1
Vetteth, S.2
Periyasamy, S.M.3
Kanj, M.4
Fedorova, L.5
Khouri, S.6
Kahaleh, M.B.7
Xie, Z.8
Malhotra, D.9
Kolodkin, N.I.10
Lakatta, E.G.11
Fedorova, O.V.12
Bagrov, A.Y.13
Shapiro, J.I.14
-
39
-
-
0024321898
-
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
-
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators
-
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406-412, 1989
-
(1989)
N Engl J Med
, vol.321
, pp. 406-412
-
-
-
40
-
-
1842839899
-
Willingness of patients to switch from conventional to daily hemodialysis: looking before we leap
-
Halpern SD, Berns JS, Israni AK: Willingness of patients to switch from conventional to daily hemodialysis: looking before we leap. Am J Med 116:606-612, 2004
-
(2004)
Am J Med
, vol.116
, pp. 606-612
-
-
Halpern, S.D.1
Berns, J.S.2
Israni, A.K.3
-
41
-
-
0038003150
-
An operating cost comparison between conventional and home quotidian hemodialysis
-
Kroeker A, Clark WF, Heidenheim AP, Kuenzig L, Leitch R, Meyette M, Muirhead N, Ryan H, Welch R, White S, Lindsay RM: An operating cost comparison between conventional and home quotidian hemodialysis. Am J Kidney Dis 42:49-55, 2003
-
(2003)
Am J Kidney Dis
, vol.42
, pp. 49-55
-
-
Kroeker, A.1
Clark, W.F.2
Heidenheim, A.P.3
Kuenzig, L.4
Leitch, R.5
Meyette, M.6
Muirhead, N.7
Ryan, H.8
Welch, R.9
White, S.10
Lindsay, R.M.11
|